Alzamend Neuro (NASDAQ:ALZN) Director Milton Ault III Sells 20,397 Shares

Alzamend Neuro, Inc. (NASDAQ:ALZN) Director Milton Ault III sold 20,397 shares of the firm’s stock in a transaction on Thursday, October 9th. The shares were sold at an average price of $2.32, for a total value of $47,321.04. Following the completion of the transaction, the director owned 8,260 shares in the company, valued at $19,163.20. The trade was a 71.18% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Alzamend Neuro Stock Performance

Shares of ALZN stock opened at $2.18 on Friday. The stock’s fifty day moving average is $2.40 and its two-hundred day moving average is $3.89. Alzamend Neuro, Inc. has a fifty-two week low of $2.06 and a fifty-two week high of $17.10.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on ALZN shares. Ascendiant Capital Markets decreased their price objective on Alzamend Neuro from $45.00 to $42.00 and set a “buy” rating on the stock in a report on Thursday, September 25th. Wall Street Zen lowered Alzamend Neuro from a “hold” rating to a “sell” rating in a report on Saturday, August 9th. Finally, Weiss Ratings reiterated a “sell (e)” rating on shares of Alzamend Neuro in a report on Saturday, September 27th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Alzamend Neuro has a consensus rating of “Hold” and a consensus price target of $42.00.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Alzamend Neuro stock. Citadel Advisors LLC acquired a new position in shares of Alzamend Neuro, Inc. (NASDAQ:ALZN) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 30,638 shares of the company’s stock, valued at approximately $36,000. Citadel Advisors LLC owned about 0.56% of Alzamend Neuro at the end of the most recent quarter. Institutional investors and hedge funds own 49.61% of the company’s stock.

Alzamend Neuro Company Profile

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.